POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Chris Horvath, as Executive Vice President, Commercial. Mr. Horvath brings almost twenty years of experience in the pharmaceutical industry, having led or worked on the launch of a number of key oncology products, including Pluvicto (lutetium 177Lu vipivotide tetraxetan), Locametz (gallium 68Ga gozetotide), Nubeqa (darolutamide), and Zytiga (abiraterone acetate). In his new role at POINT, Mr. Horvath will lead the commercial strategy for POINT’s pipeline.

“With only a handful of approved therapeutic radiopharmaceuticals in oncology, experienced leaders in the field are in short supply,” said Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. “Chris’ significant experience in the commercialization of radiopharmaceuticals for the treatment of prostate cancer, as well as his experience with pan-tumor products, positions him to add significant value to POINT’s platform. As one of the founders of POINT, I continue to be amazed by the quality of talent that has assembled at this company and am grateful to be part of this team of radiopharmaceutical experts. Together, we are writing the next chapter of radiopharmaceutical therapy.”